“I think it’s really important that people keep signing up to these type of trials to push research forward.”
A trial looking at decitabine for myelodysplastic syndrome and acute myeloid leukaemia (DEC-MDS)
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial was for people with
Cancer Research UK supported this trial.
More about this trial
Myelodysplastic syndrome (MDS) is a condition affecting the
MDS can sometimes develop into acute myeloid leukaemia (AML). If you have a lot of abnormal cells in your bone marrow, there is a higher risk of the MDS becoming AML. Doctors may call this high risk MDS.
Doctors often treat high risk MDS with
The researchers hoped that a new drug called decitabine may be able to help treat people with high risk MDS and AML.
The aims of this trial were to find out
- how well decitabine works for people with MDS and AML
- the side effects of giving decitabine to people with MDS and AML
Summary of results
We have contacted the trial team who tell us they don’t expect to be making results available for this trial.
The trial closed early. The trial team have told us that this was mainly due to poor recruitment and because decitabine was not a successful treatment in the few people who did join the trial.
How to join a clinical trial
Prof Ghulam Mufti
Cancer Research UK
King's College London
Kings College Hospital NHS Foundation Trust
NIHR Clinical Research Network: Cancer
This is Cancer Research UK trial number CRUKE/09/040.